Hydroxychloroquine Fact Sheet Part 3: Proof is in the Sources!

See part 1 and part 2 of the HCQ fact sheet! HCQ is SAFE and EFFECTIVE. Not only that, but the evidence is mounting. Check out the sources in the Frontline Doctors' White Paper. How much longer can frauds like Fauci hide the truth?

America’s Frontline Doctors published the following in their White Paper: x 

[S]even months into the pandemic there is overwhelming evidence accumulating that HCQ is also effective for Covid-19. There are dozens of studies demonstrating its effectiveness from all around the world. From China to France to Saudi Arabia to Iran to Italy to India to New York City to Michigan to Brazil. 

This is not surprising. As far back as [2005], chloroquine (CQ) the first cousin of HCQ and previously known to be effective against SARS-CoV-1, was stated by China to be a treatment for Covid-19. 

• February 19, 2020 China: “The drug [chloroquine] is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People’s Republic of China for the treatment of [COVID-19] infection in larger populations in the future.”xi

• March 4, 2020: France: “The first results obtained from more than 100 patients show the superiority of chloroquine compared with treatment of the control group in terms of reduction of exacerbation of pneumonia, duration of symptoms and delay of viral clearance all in the absence of severe side effects.”xii

• March 20, 2020: New York: 1450 patients. 1045 mild and not requiring meds (all recovered), 405 treated with HCQ + AZM + Zinc of which six were hospitalized and two died.xiii • March 22, 2020: India: The country of India recommends HCQ prophylaxis broadly.xiv

• March 22, 2020: China: “Among patients with Covid-19, HCQ could significantly shorten time to complete recovery and promote the absorption of pneumonia.”xv

• April 11, 2020: France: All patients [treated with HCQ + AZM] improved clinically except [two]... A rapid fall of nasopharyngeal viral load was noted. ... Patients were able to be rapidly discharged from IDU [Infectious Disease Unit]...”xvi

• April 13, 2020: NY: 54 long-term care/nursing home patients received HCQ+ Doxycycline and only 5.6% died. (this population can have >50% mortality) xvii xviii • April 17, 2020: Brazil: Of 636 symptomatic high-risk outpatients, only 1.9% of those treated needed hospitalization vs., 5.4% of the untreated.xix

• April 21, 2020: 16 countries: “The difference in dynamics of daily deaths is so striking that we believe that the urgency context commands presenting the analysis ...”xx xxi

• April 24, 2020: Iran: Hydroxychloroquine ...can be potential treatment options. xxii

• April 30, 2020: Saudi Arabia: “Chloroquine and hydroxychloroquine have antiviral characteristics in vitro. The findings support the hypotheses that these drugs have efficacy in the treatment of COvid-19.”xxiii

• May 15, 2020: China: We found that fatalities are 18.8% in the HCQ group, significantly lower than 47.4% in the non-HCQ group. These data demonstrate that addition of HCQ on top of the basic treatments is highly effective in reducing the fatality of critically ill patients of Covid-19 through attenuation of inflammatory cytokine storm. Therefore, HCQ should be prescribed as a part of treatment for critically ill Covid-19 patients, with possible outcome of saving lives. 29 xxiv

• May 16, 2020: France: 1061 Covid-positive patients treated with HCQ+AZM “no cardiac toxicity was observed” and “good clinical outcome and virological cure were seen in 92%.xxv

• June 6, 2020: France: “In conclusion, a meta-analysis of publicly available clinical reports demonstrates that chloroquine ... reduces mortality by a factor 3 in patients infected with Covid-19.” xxvi 

• June 20, 2020: India: “Consumption of four or more maintenance doses of HCQ was associated with a significant decline in the odds of getting infected... This study provides actionable information for policymakers to protect healthcare workers at the forefront of Covid-19 response.” xxvii xxviii 

• June 29, 2020: Portugal: The odds ratio of [Covid-19] infection in patient with chronic treatment with HCQ is half.xxix 

• June 29, 2020: Detroit: “In this multi-hospital assessment, when controlling for Covid-19 risk factors, treatment with HCQ alone and in combination with AZM was associated with reduction in Covid-19 mortality.”xxx 

• June 30, 2020: NYC: 6493 patients who had laboratory confirmed Covid- 19 with clinical outcomes between March 13-April 17, 2020 who were seen in 8 hospitals and 400 clinics in the NYC metropolitan area. “Hydroxychloroquine use was associated with decreased mortality.”xxxi 

• July 3, 2020: NY: Covid-positive patients treated with HCQ + AZM + Zinc vs. untreated.xxxii 

• hospitalized: treated 2.8% vs. untreated 15.4% 

• death: treated 0.7% vs. untreated 3.5%, 

• No cardiac side effects 

• 5x less all-cause deaths

 There is a preponderance of evidence that hydroxychloroquine is safe. And when combined with a full treatment of the recommended drugs to treat COVID-19, it can have a powerful impact to save lives. 

Making sense of confusing information: 

Since the 1950s, doctors have known that overdosing on hydroxychloroquine can cause heart arrhythmia. This is one of the facts shared by America’s Frontline Doctors. Overdosing on almost ANY medication will cause problems. Even too much Tylenol can be deadly due to acetaminophen overdose.xxxiii 

In spite of this public knowledge, a pharmaceutical company in Brazil "Farmanguinhos," (translated the Institute of Technology in Pharmaceuticals) funded a study to overdose COVID-19 patients on 1,200 mg of chloroquine (CQ), which is a stronger cousin to HCQ. Eleven people died.xxxiv 

By comparison, Lupus patients commonly take 100-200 mg of HCQ twice a day. As a prophylaxis (to prevent malaria) people will take 310 mg base once a week. To treat malaria, they will take 620 mg base max. That is half the dose of the weaker cousin drug to what was used in this "study." In addition, this study used roughly 6 times the dose given to Lupus patients. 

Yet, this rigged "study" was trumpeted across the news to discredit HCQ, even though its stronger cousin (CQ) was used at a very high dose. One article is titled, "Hydroxychloroquine: Using anti-malaria drug is a risky business"xxxv with the preview text stating, "Fatal study in Brazil. A small phase II study in Brazil, in which 11 patients died ..." A large section of the article criticizes President Trump and other leaders who support HCQ. 

Why would large pharmaceutical companies want to discredit HCQ? Because billions are at stake with a vaccine. This illustrates how cherry picking "facts" to completely change the perspectives of doctors can manipulate you based on misinformation. 

One of the locations that is filing online prescriptions for hydroxychloroquine to patients with a confirmed diagnosis of COVID-19 is https://www.healthwarehouse.com/-94847.html. Lives are hanging in the balance right now. 

Liberty Counsel Action is a policy organization dedicated to educating Americans and giving them the tools to understand our world to help restore our nation. We rely on the partnership and donations of individuals and organizations to further this vision in America and beyond. Learn more and support our ministry at www.LCAction.org.

x Gold, Simone. America’s Frontline Doctors. White Paper on Hydroxychloroquine. (Accessed: 2020, August 4). https://drive.google.com/file/d/1-gsn_Ye2EYDDkV_79Ag1tgUqZLNCMSt-/view. 

xi Gao, Jianjun, Zhenzue Tian, and Xu Yang. BioScience Trends. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. (Received: 2020, February 18. Published: 2020, March 16). https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_article 
xii Colson, Philippe, Jean-Marc Rolan, Jean-Christophe Lagier, Philippe Brouqui, and Didier Raoult. National Center for Biotechnology Information: National Institutes for Health. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. (2020, March 4). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135139. 

xiii Risch, Harvey A. American Journal of Epidemiology in partnership with Johns Hopkin Bloomberg School of Public Health and Oxford Academic. Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis. (2020 May 27). https://academic.oup.com/aje/article/doi/10.1093/aje/kwaa093/5847586. 

xiv Bhargava, Balram. Ministry of Health and Family Welfare: Government of India. Advisory of the use of hydroxychloroquine as prophylaxis for SARS-CoV-2 infection. (2020, March 22). https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf. 

xv Chen. Zhaowei, Jijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, and Zhan Zhang. MedRXIV in partnership with Yale, BMJ (Formerly the British Medical Journal) and the Cold Spring Harbor Laboratory. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. (2020, April 10). https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3. 

xvi Gautret, Philippe. Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb, Jacques Sevestre, Morgane Mailhe, Barbara Doudier, Camille Aubry, Sophie Amrane, Piseth Seng, Marie Hocquart, Carole Eldin, Julie Finance, Vera Esteves Vieira, et al. Science Direct. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. (Received: 2020, April 3, Published: 2020, April 11). https://www.sciencedirect.com/science/article/pii/S1477893920301319. 

xvii ABC News. Coronavirus News: Long Island doctors embrace combination drug therapy in fighting COVID-19. (2020 April 13). https://abc7ny.com/coronavirus-treatment-long-island-news-nassau-county/6093072/. 

xviii Yu, Bo, Chenze Li, Peng Chen, Ning Zhou, Luyun Wang, Jia Li, Hualiang Jiang, and Dao-Wen Wang. PubMed.gov of National Library of Medicine: National Institutes of Health. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. (2020, May 15). https://pubmed.ncbi.nlm.nih.gov/32418114/. 

xix Rodrigo Barbosa Esper M.D., Ph.D., Rafael Souza da Silva M.D., Fernando Teiichi Costa Oikawa M.D., Ph.D., Marcelo Machado Castro M.D., Alvaro Razuk-Filho M.D., Ph.D., Pedro Benedito Batista Junior M.D., Sergio Wilhelm Lotze M.D., Cleber Nunes da Rocha M.D., Roberto de Sá Cunha Filho M.D., Saulo Emanuel Barbosa de Oliveira M.D, Philipe Leitão Ribeiro, M.D., Valéria Cristina Vigar Martins M.D., Fernando Silva Braga Bueno M.D., Priscila Ligeiro Gonçalves Esper M.D., and Eduardo Fagundes Parrillo M.D.. Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine. (Accessed 2020, July 7). https://pgibertie.files.wordpress.com/2020/04/2020.04.15-journal-manuscript-final.pdf. 

xx Izoulet, Maxime. SSRN (formerly known as Social Science Research Network). Countries which Primarily Use Antimalarial Drugs As COVID-19 Treatment See Slower Dynamic of Daily Deaths. (2020, April 21). https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3575899. 

xxi Izoulet, Maxime. MedRXIV in partnership with Yale, BMJ (Formerly the British Medical Journal) and the Cold Spring Harbor Laboratory. National Consumption of Antimalarial Drugs and COVID-19 Deaths Dynamics : an Ecological Study. (2020, May 28). https://www.medrxiv.org/content/10.1101/2020.04.18.20063875v2. 

xxii Ashraf, Mohammad. Nasim Shokouhi, Elham Shirali, Fateme Davari-tanha, Omeed Memar, Alireza Kamalipour, Ayein Azarnoush, Avin Mabadi, Adele Ossareh, Milad Sanginabadi, Talat Azad, Leila Aghaghazvini, Sara Ghaderkhani, Tahereh Poordast, Alieh Pourdast, and Pershang Nazemi. ResearchGate. COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes. (2020, May). https://www.researchgate.net/publication/341197843_COVID19_in_Iran_a_comprehensive_investigation_from_exposure_to_treatment_outcomes. 

xxiii Meo, Sultan Ayoub. D.C. Klonoff, and J. Akram. European Review for Medical and Pharmacological Sciences. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. (2020). (https://www.europeanreview.org/wp/wp-content/uploads/4539-4547.pdf. 

xxiv Yu, Bo, Chenze Li, Peng Chen, Ning Zhou, Luyun Wang, Jia Li, Hualiang Jiang, and Dao-Wen Wang. PubMed.gov of National Library of Medicine: National Institutes of Health. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. (2020, May 15). https://pubmed.ncbi.nlm.nih.gov/32418114/. 

xxv Million, Matthieu. Jean-Christophe Lagier, Philippe Gautret, et al. Méditerranée Infection. Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France. (Accessed 2020, July 29). https://www.mediterranee-infection.com/wp-content/uploads/2020/04/MS.pdf. 

xxvi Million, Matthieu. Philippe Gautretac, Philippe Colson, Yanis Roussel, Gregory Dubourg, Eric Chabriere, Stéphane Honore, Jean-Marc Rolain, Florence Fenollar, Pierre-Edouard Fournier, Jean-Christophe Lagier, Philippe Parola, Philippe Brouqui, and Didier Raoult. Science Direct. Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world. (2020, June 6). https://www.sciencedirect.com/science/article/pii/S2052297520300615. 

xxvii Chatterjee, Pranab. Tanu Anand, Kh Jitenkumar Singh, Reeta Rasaily, Ravinder Singh, Santasabuj Das, Harpreet Singh, Ira Praharaj, Raman R Gangakhedkar, Balram Bhargava, and Samiran Panda. Indian Journal of Medical Research: Indian Council of Medical Research. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. (2020, June 20). http://www.ijmr.org.in/article.asp?issn=0971- 5916;year=2020;volume=151;issue=5;spage=459;epage=467;aulast=Chatterjee. xxviiiChatterjee, Pranab. Tanu Anand, Kh Jitenkumar Singh, Reeta Rasaily, Ravinder Singh, Santasabuj Das, Harpreet Singh, Ira Praharaj, Raman R Gangakhedkar, Balram Bhargava, and Samiran Panda. National Center for Biotechnology Information at the National Library of Medicine of the National Institutes of Health. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. (2020, July 3). https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32611916. 

xxix Ferreira, Antonio. Antonio Oliveira-e-Silva, and Paulo Bettencourt. MedRXIV in partnership with Yale, BMJ (Formerly the British Medical Journal) and the Cold Spring Harbor Laboratory. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. (2020, June 29). https://www.medrxiv.org/content/10.1101/2020.06.26.20056507v1. 

xxx Arshada, Samia. Paul Kilgore, Zohra S. Chaudhry, Gordon Jacobsen, Dee Dee Wang, Kylie Huitsing, Indira Brar, George J. Alangaden, Mayur S. Ramesh, John E. McKinnon, William O’Neill, Marcus Zervos, and Henry Ford COVID19 Task Force. International Journal of Infectious Diseases. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. (Received first version: 2020, May 28, Published: 2020, June 29). https://www.ijidonline.com/action/showPdf?pii=S1201-9712%2820%2930534-8. 

xxxi Mikami, T., Miyashita, H., Yamada, T. et al. Journal of General Internal Medicine. Risk Factors for Mortality in Patients with COVID-19 in New York City. (Published 2020, June 30). https://link.springer.com/article/10.1007%2Fs11606-020-05983-z. 

xxxii Scholz, Martin. Roland Derwand , and Vladimir Zelenko. Preprints. COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study. (Received: 2020, June 30, Published: 2020, July 3). https://www.preprints.org/manuscript/202007.0025/v1. 

xxxiii Saljoughian, Manouchehr. U.S. Pharmacist. Acetaminophen Intoxication: A Critical-Care Emergency (2016, December 16). https://www.uspharmacist.com/article/acetaminophen-intoxication-a-criticalcare-emergency. 

xxxiv Borba, Mayla Gabriela Silva. Fernando de Almeida Val, Vanderson Sousa Sampaio, et al. MedRXIV. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, doubleblinded, phase IIb clinical trial (CloroCovid-19 Study). (2020, April 16). https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v2. 

xxxv Freund, Alexander. Deutsche Welle. Hydroxychloroquine: Using anti-malaria drug is a risky business. (2020, May 19). https://www.nytimes.com/2020/04/12/health/chloroquine-coronavirus-trump.html.